Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-15

Study Completion Date

2020-08-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the analgesic effect of Omnitram for the treatment of painful diabetic neuropathy. Each subject with diabetic neuropathy will be treated for four weeks with Omnitram and for four weeks with placebo. The order of the Omnitram and placebo treatment will be random.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Comparing the Effectiveness and Safety of Tramadol HCl/Acetaminophen Versus Placebo for the Treatment of Painful Neuropathy in Diabetic Patients

NCT00210847

Diabetic Neuropathies

COMPLETED PHASE3

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365

Diabetic Peripheral Neuropathy

COMPLETED PHASE2

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

NCT01087203

Diabetic Peripheral Neuropathy

TERMINATED PHASE2

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01345045

Diabetic Neuropathic Pain

COMPLETED PHASE2

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

NCT00113620

Pain Diabetic Neuropathy

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A multi-centered, randomized, double-blind, placebo-controlled, two-period cross-over study to compare the safety and efficacy of Omnitram (30 mg to 120 mg daily) and placebo in patients with painful diabetic polyneuropathy. For subjects receiving treatment for neuropathic pain prior to study enrollment, their treatment will be tapered and stopped at least 2 weeks before they will be enrolled. Approximately fifty subjects will be randomized in a double-blind manner to a 4-week treatment period of Omnitram or placebo. After a washout of at least one week, patients will cross-over to the other treatment for a second 4 week treatment period with Omnitram or placebo.

During the first two weeks of each treatment period, guided by efficacy and tolerability, the dose will be increased from 3 tablets to 12 tablets per day given in three equal doses at approximately at 8 am, 2 pm and 8 pm (i.e., if the tablet is Omnitram, 30, 60, 90 or 120 mg/day). During the final two weeks of the treatment period, the doses will be kept constant at the highest tolerated titrated dose. Up to six tablets daily of 500 mg oral acetaminophen can be used as rescue medication except on the last 4 days of each treatment segment (Days 26, 27, 28, and 29).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Neuropathies Neuropathic Pain Pain, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Omnitram

Oral Omnitram (10 mg tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet (10 mg) and 4 tablets (40 mg) to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.

Group Type EXPERIMENTAL

Omnitram Oral Tablet

Intervention Type DRUG

Administered three times daily for 28 consecutive days.

Placebo

Oral placebo (tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet and 4 tablets to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.

Group Type PLACEBO_COMPARATOR

Placebo Oral Tablet

Intervention Type DRUG

Administered three times daily for 28 consecutive days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omnitram Oral Tablet

Administered three times daily for 28 consecutive days.

Intervention Type DRUG

Placebo Oral Tablet

Administered three times daily for 28 consecutive days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female between the ages of 18 and 75 years of age.
2. Diabetes mellitus diagnosis for at least 6 months.
3. Total glycosylated hemoglobin of \<=12%.
4. Antidiabetic therapy used at screening will not be changed during the study.
5. Clinical diagnosis, confirmed by the Investigator, of painful diabetic neuropathy with symptoms and signs for at least 6 months.
6. Lower extremity pain, from diabetic neuropathy, present daily for the previous 3 months.
7. Patients currently requiring opioid treatment must be taking daily doses of an opioid-based analgesic equivalent to \<=160mg of oral morphine.
8. Average neuropathic pain intensity over last 3 days before randomization (Segment 1, Study Day 1) of at least 4 on a 0-10 scale (0 = no pain; 10 = the worst possible pain).
9. Diabetic neuropathy confirmed by 1 of the following:

* Clinical signs (distal sensory disturbance/lack of distal deep tendon reflexes).
* Electrophysiological tests (slowing of nerve conduction or reduction of amplitude of sensory action potential).
* Abnormal quantitative sensory testing (reduction or absence of pin sensibility and/or vibration sensibility on Total Neuropathy Score - Nurse (TNSn) examination in lower and/or upper extremities at screening.
10. Able and willing to give informed consent.
11. Able to comply with all study procedures.
12. If female, must not be of childbearing potential or must agree to use one or more of the following forms of contraception during screening and for 30 days following study drug dosing: hormonal (e.g., oral, transdermal, intravaginal, implant or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6 months minimum); or abstinence; or bilateral tubal ligation (if no conception post-procedure).
13. Complete blood count (CBC) within normal range for the testing facility or not clinically significant.
14. Electrocardiogram (ECG), AST, ALT, and urinalysis values within the normal range for the testing facility or not clinically significant.
15. Normal renal function: Glomerular filtration rate (GFR) calculated by Cockcroft-Gault formula \> 60 ml/min.
16. Negative pregnancy test within 1 week of Segment 1, Study Day 1.
17. Negative urine test for substances of abuse per CRU standards.
18. Negative serology tests for HIV, hepatitis B surface antigen, and hepatitis C virus antibody.
19. Body Mass Index (BMI) 19.0 to 40 kg/m.

Exclusion Criteria

1. Clinically significant abnormal vital signs including oral temperature \> 38°C or history of current illness.
2. Inability to exclude other causes of polyneuropathy including: alcoholism, vitamin B12 deficiency, endocrinopathies, vasculitides, heavy metal exposure, drug use, and malignancy (direct or paraneoplastic).
3. History of seizures, epilepsy, or recognized increase risk of seizure (e.g. head trauma, metabolic disorders, alcohol and drug withdrawal).
4. History of cirrhosis or laboratory evidence of liver disease.
5. Use of serotonergic drugs and drugs that impair serotonin metabolism (e.g., mirtazapine, trazodone); monoamine oxidase inhibitors, including linezolid, methylene blue; serotonin and norepinephrine reuptake inhibitors, except fluoxetine, within 14 days of Segment 1, Study Day 1 or during the study, use of fluoxetine within 28 days of Segment 1, Study Day 1, or during the study; and selective serotonin re-uptake inhibitors. Use of tricyclic antidepressants and other tricyclic drugs including cyclobenzaprine and promethazine; triptans; 5-HT3 receptor antagonists; neuroleptics. Use of benzodiazepines or other central nervous system depressants including non-benzodiazepine sedative hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics within 14 days of Segment 1, Study Day 1, or during the study. Use of opiates, including tramadol, within 28 days of Segment 1, Study Day 1, or during the study. Use of all other analgesics, except acetaminophen, within 14 days of Segment 1, Study Day 1, or during the study.
6. History of previous anaphylaxis, severe allergic reaction to tramadol, codeine or other opioid drugs.
7. Contraindication to use of opioids, tramadol, or acetaminophen.
8. Use of non-pharmacological pain therapy.
9. Any other unstable acute or chronic disease that could interfere with the evaluation of the safety of the study drug as determined by the principal Investigator in dialogue with the Sponsor's Medical Monitor.
10. Currently pregnant or breast-feeding a child.
11. Unlikely to comply with the study protocol.
12. Known or suspected alcohol or drug abuse within the past 12 months.
13. Received another investigational agent within 4 weeks before screening visit, or receiving any other investigational agent during this study.
14. Any concurrent disease or condition that in the opinion of the investigator impairs the subject's ability to complete the trial. Psychological, familial, sociological, geographical or medical conditions which, in the Investigator's opinion, could compromise compliance with the objectives and procedures of this protocol or obscure interpretation of the trial's data.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No